Regeneron's 2025 outlook includes defensive capital allocation, competitive pressure on Eylea, et cetera. Click here to read ...

Immuneering (IMRX) announced a clinical supply agreement with Regeneron Pharmaceuticals (REGN) for its anti-PD-1 therapy, Libtayo. The supply ...

Immuneering Corporation (IMRX), a clinical-stage oncology company, Thursday said it has signed a clinical supply agreement with ...

Life sciences real estate developer IQHQ has refinanced its debt on two properties in Fenway and another in Brighton.

The Altamonte Springs-based nonprofit health system began work Feb. 5 on the 13,700-square-foot, 12-bed AdventHealth Meadow ...